Published: 5 January 2024
Author(s): Aldostefano Porcari, Gianfranco Sinagra, Julian D Gillmore, Marianna Fontana, Philip N Hawkins
Issue: May 2024
Section: Review Article

Transthyretin amyloid cardiomyopathy (ATTR-CM) has been traditionally considered a rare and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart failure (HF) and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have transformed the diagnosis of ATTR-CM, which is now possible without recourse to endomyocardial biopsy in ≈70 % of cases. Many patients are now diagnosed at an earlier stage.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.